Larimar Therapeutics 過去の業績

過去基準チェック /06

Larimar Therapeuticsの収益は年平均-7.8%で減少しているが、Biotechs業界はgrowingで19.3%年平均の収益となった。

主要情報

-7.8%

収益成長率

36.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-32.6%
ネット・マージン	n/a
前回の決算情報	30 Sep 2024

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

収支内訳

Larimar Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:LRMR 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Sep 24	-65	17	57
30 Jun 24	-58	16	50
31 Mar 24	-45	15	36
31 Dec 23	-37	14	28
30 Sep 23	-33	14	24
30 Jun 23	-33	13	23
31 Mar 23	-33	12	23
31 Dec 22	-35	12	24
30 Sep 22	-35	12	23
30 Jun 22	-44	12	32
31 Mar 22	-47	12	35
31 Dec 21	-51	12	38
30 Sep 21	-56	13	43
30 Jun 21	-49	14	36
31 Mar 21	-48	13	35
31 Dec 20	-42	11	31
30 Sep 20	-34	9	26
30 Jun 20	-33	6	27
31 Mar 20	-25	4	22
31 Dec 19	-23	2	21

質の高い収益: LRMRは現在利益が出ていません。

利益率の向上: LRMRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: LRMRは利益が出ておらず、過去 5 年間で損失は年間7.8%の割合で増加しています。

成長の加速: LRMRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: LRMRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: LRMRは現在利益が出ていないため、自己資本利益率 ( -32.65% ) はマイナスです。

Larimar Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06